Patents Examined by Julie Ha
  • Treating IgE-mediated allergic diseases
    Patent number: 11439682
    Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: September 13, 2022
    Assignee: Oneness Biotech Co., Ltd.
    Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 11434275
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 6, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • Atomic description of immune complex that causes heparin-induced thrombocytopenia
    Patent number: 11435362
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 6, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Collagen peptide-based medicament compositions and devices and methods of production and use thereof
    Patent number: 11433112
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: September 6, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard Eric Schlumpf, Robert Baratta, Shawn A. Delorey
  • Methods for regulating free fatty acid flux using fat specific protein 27 (FSP27) compositions
    Patent number: 11433117
    Abstract: Methods and FSP27 compositions for treating and/or preventing metabolic disease and conditions associated insulin resistance, obesity, inflammation and dyslipidemia are described.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: September 6, 2022
    Assignee: Ohio University
    Inventors: Vishwajeet Puri, John Kopchick, Vishva Sharma
  • Compounds (immunorhelins)
    Patent number: 11434258
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 6, 2022
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Detection and treatment of demyelinating diseases
    Patent number: 11435345
    Abstract: The present invention relates to methods of detecting, diagnosing and distinguishing between demyelinating diseases such as Multiple Sclerosis. The present invention also relates to methods of treating, and peptides for use in the treatment of, demyelinating diseases such as Multiple Sclerosis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 6, 2022
    Assignee: MATN SCIENTIFIC LIMITED
    Inventors: Mahmoud Sedaghati, Mahsa Sedaghati, Tina Sedaghati
  • Peptides having reduced toxicity that stimulate cholesterol efflux
    Patent number: 11434267
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
    Patent number: 11426441
    Abstract: The present invention relates to a composition comprising a protein phosphatase 1 inhibitory peptide for treating vascular diseases. The composition of the present invention inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation to suppress abnormal proliferation of vascular smooth muscle cells (VSMCs), and activates eNOS of vascular endothelial cells (VECs) to induce the recovery from dysfunction, and thus can be favorably used in the treatment of vascular diseases including pulmonary hypertension.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 30, 2022
    Assignee: BethphaGen Inc.
    Inventors: Woo Jin Park, Seung Pil Jang
  • Collagen peptide-based medicament compositions and devices and methods of production and use thereof
    Patent number: 11426440
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 30, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard Eric Schlumpf, Robert Baratta, Shawn A. Delorey
  • Compositions and methods for treatment of fungal infections
    Patent number: 11427617
    Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: August 30, 2022
    Assignee: THE UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal, Virginia Basso
  • Compositions, methods and uses for treating post-traumatic stress disorder
    Patent number: 11426444
    Abstract: Compositions comprising a Teneurin C-terminal Associated Peptide—1 (TCAP-1) peptide are described with respect to methods and uses of same for preventing and/or treating post-traumatic stress disorder (“PTSD”).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 30, 2022
    Inventors: David Lovejoy, Robert Stein, Andrew Slee, Garo Armen
  • High-purity adrenocorticotropic hormone, analogue and a large-scale preparation method thereof
    Patent number: 11419919
    Abstract: The invention belongs to the technical field of polypeptide preparation methods, and in particular relates to a high-purity ACTH (human sequence) or analogue and large-scale preparation method thereof. The main steps include: amino acids are coupled from the C-terminal to the N-terminal by Fmoc solid-phase synthesis method to obtain the crude ACTH (human sequence) or analogue peptidyl-resin with protective groups, wherein the reaction temperature of C-15 peptide synthesis is 40-60° C. After cleavge and precipitation, the crude product of ACTH (human sequence) or analogue is obtained, and then the high-purity product is obtained by liquid chromatography. The chromatographic purity of ACTH (human sequence) or analogue prepared by the invention is more than 99%, the stability is good, and the yield of the target peptide is ?63%.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: August 23, 2022
    Assignee: Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
    Inventors: Jundong Meng, Kangning Rui, Bin Liu, Yuanyuan Han, Song Chen, Haoning Zhang
  • Analogues of PYY
    Patent number: 11421012
    Abstract: Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: August 23, 2022
    Assignee: IP2IPO INNOVATIONS LIMITED
    Inventor: Stephen Robert Bloom
  • Metabolite inspired selective oxytocin receptor agonists
    Patent number: 11414459
    Abstract: The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 16, 2022
    Assignee: Kinoxis Therapeutics Pty Ltd
    Inventors: Michael Kassiou, Damien Gulliver, Tristan Reekie, Timothy Katte, William Jorgensen, Eryn Werry
  • Method of managing joint pain
    Patent number: 11413327
    Abstract: A method of alleviating joint pain in a patient comprising evaluating the patient's joint pain when undergoing motions associated stress to the joint, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: August 16, 2022
    Assignee: ORTHOTROPHIX, INC.
    Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
  • Methods for treating cancer
    Patent number: 11414488
    Abstract: The present invention relates to a method of treating a cancer in a patient.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: August 16, 2022
    Assignee: BICYCLERD LIMITED
    Inventors: Gavin Bennett, Gillian Langford, Peter Park, Johanna Lahdenranta
  • CNP prodrugs with carrier attachment at the ring moiety
    Patent number: 11413351
    Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 16, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • Compositions and methods for enhancing neuro-repair
    Patent number: 11413326
    Abstract: Methods for enhancing recovery after an ischemic injury, including cerebral ischemia and stroke, by administration of therapeutic amounts of Domain V protein are described.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 16, 2022
    Assignee: University of Kentucky Research Foundation
    Inventor: Gregory J. Bix
  • Cell-penetrating compstatin analogs and uses thereof
    Patent number: 11407789
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 9, 2022
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber